KR20140114709A - Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract - Google Patents
Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract Download PDFInfo
- Publication number
- KR20140114709A KR20140114709A KR1020130029414A KR20130029414A KR20140114709A KR 20140114709 A KR20140114709 A KR 20140114709A KR 1020130029414 A KR1020130029414 A KR 1020130029414A KR 20130029414 A KR20130029414 A KR 20130029414A KR 20140114709 A KR20140114709 A KR 20140114709A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- present
- skin
- thunb
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 241000674252 Boehmeria spicata Species 0.000 title claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 230000037303 wrinkles Effects 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 230000003779 hair growth Effects 0.000 claims description 18
- 230000006872 improvement Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 240000006439 Aspergillus oryzae Species 0.000 claims description 9
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 47
- 210000004027 cell Anatomy 0.000 abstract description 27
- 108010035532 Collagen Proteins 0.000 abstract description 17
- 102000008186 Collagen Human genes 0.000 abstract description 17
- 229920001436 collagen Polymers 0.000 abstract description 17
- 210000002950 fibroblast Anatomy 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 210000004209 hair Anatomy 0.000 abstract description 5
- 210000003470 mitochondria Anatomy 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 230000009456 molecular mechanism Effects 0.000 abstract description 3
- 230000028993 immune response Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 46
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 240000000249 Morus alba Species 0.000 description 20
- 235000008708 Morus alba Nutrition 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241000228212 Aspergillus Species 0.000 description 17
- 201000004384 Alopecia Diseases 0.000 description 16
- 229960005188 collagen Drugs 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000006071 cream Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- -1 3-butylene glycol Chemical compound 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 230000003676 hair loss Effects 0.000 description 11
- 102000029816 Collagenase Human genes 0.000 description 10
- 108060005980 Collagenase Proteins 0.000 description 10
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 10
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 10
- 208000024963 hair loss Diseases 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229960002424 collagenase Drugs 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036570 collagen biosynthesis Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003966 growth inhibitor Substances 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 229940080817 rotenone Drugs 0.000 description 3
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 2
- 230000037450 immune related reaction Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 241001494246 Daphnia magna Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001646071 Prioneris Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 좀깨잎나무 추출물을 유효성분으로 포함하는 피부 상태 개선용 조성물에 관한 것이다. The present invention relates to a composition for improving skin condition comprising an extract of Aspergillus species as an active ingredient.
피부는 노화가 일차적으로 나타나는 기관으로 이를 지연 또는 예방하기 위하여 화장품 영역에서도 많은 연구가 진행되어 왔다. 통상적으로 피부노화는 25세를 전후하여 진행되기 시작하여 40세를 전후한 시기에 본격적으로 피부노화가 진행된다. 피부노화의 대표적 현상으로 피지 분비량이 감소되어 피부가 건조해지고, 세포 재생이 늦어지고, 노화 각질이 많이 쌓여서 피부가 거칠어지는 특징이 있다. 또한, 표피를 지탱해주는 콜라겐의 합성양이 감소되고 엘라스틴(탄력섬유)이 변성되어 주름이 생긴다. 아울러, 피부색이 얼룩지고 기미, 검버섯 등 과 색소 침착 증상이 나타나며, 표피가 얇아져서 피부보호 기능이 약화된다. 그 밖의 현상으로는 피부 두께의 감소와 관련된 피부 장벽작용(Barrier Effect)의 저하로 인한 피부 트러블의 증가를 들 수 있다. 피부노화와 관련된 연구는 크게 피부노화의 주요원인이 되는 자외선과 활성산소로부터 피부를 보호하는 소재, 피부주름 개선 소재, 피부탄력 증진 소재, 피부 보습력 강화소재, 기미 생성억제에 관련된 소재로 분류할 수 있다. Skin is the primary organ of aging, and much research has been done in the field of cosmetics to delay or prevent it. Skin aging usually begins around the age of 25, and skin aging proceeds in earnest at around the age of 40 years. As a representative phenomenon of skin aging, sebum secretion is reduced, skin becomes dry, cell regeneration is delayed, and aging skin is piled up and skin becomes rough. In addition, the synthesis amount of collagen which supports the epidermis is reduced, and elastin (elastic fiber) is denatured to form wrinkles. In addition, skin color stains, spots, black spots and pigmentation symptoms appear, the skin is thinned, the skin protection function is weakened. Other phenomena include an increase in skin troubles due to a decrease in the skin barrier effect (barrier effect) associated with a decrease in skin thickness. Researches related to skin aging are classified into materials that protect skin from ultraviolet rays and active oxygen, which are major causes of skin aging, skin wrinkle improving materials, skin elasticity enhancing materials, skin moisturizing materials, have.
피부에 노화가 진행되면 진피의 변화가 현저하게 나타나며, 70세 이후 나타나는 진피위축은 대표적인 노화현상이다. 진피의 변화는 섬유아세포(fibroblast)의 숫자와 이들의 합성 능력의 감소로 인하여 세포 외 기질 중 큰 분자량을 가진 물질들의 변화로 발생된다. 그 구체적인 변화는 콜라겐 다발의 분리, 점다당질 합성감소, 콜라겐과 탄력섬유(elastin)수와 직경 감소, 콜라겐과 탄력섬유 분쇄 및 혈관의 팽창 등을 들 수 있다. 일반적으로 피부의 수분 함유량, 콜라겐 함유량 및 외부 환경에 대한 면역 작용 능력 등 여러 가지 복합적인 요인들 중 주름의 형성에 가장 큰 영향을 미치는 것은 콜라겐의 생성량과 콜라겐의 함량을 감소시키는 콜라겐 분해 효소인 콜라게네이즈의 발현량과 활성이다. 좀깨잎나무 추출물의 콜라겐과 콜라게네이즈 효소에 미치는 영향은 전혀 밝혀져 있지 않았다. Dermatological atrophy is a typical aging phenomenon after 70 years of age. Changes in the dermis are caused by a change in the number of fibroblasts and a change in the molecular weight of the extracellular matrix due to a decrease in their ability to synthesize. Specific changes include separation of collagen bundles, reduction of point polysaccharide synthesis, reduction in the number and diameter of collagen and elastic fibers, collagen and elastic fiber grinding, and expansion of blood vessels. Generally, among the various complex factors such as moisture content of the skin, collagen content, and immunity to the external environment, collagen degradation enzymes such as collagenase, collagenase and collagen, which reduce collagen production and collagen content, It is the active amount and activity of the genesis. Collagen and collagenase enzymes of A. zeaxus extract were not known to be affected at all.
한편, 환경오염, 자동차 배기가스 등으로 인해 호르몬 불균형 현상이 심화되고 있다. 이로 인해 탈모 발생률이 높아지고, 발생연령도 낮아지고 있으며, 피부면역시스템의 부조화가 초래되어 아토피, 건선과 같은 다양한 피부질환 등이 발생하고 있다. 또한 인스턴트 음식, 육류중심으로의 식생활 변화로 어린 나이에도 불구하고 비만으로 고통을 받고 있는 인구가 급격히 증가하고 있다.On the other hand, hormone imbalance is increasing due to environmental pollution and automobile exhaust gas. As a result, the rate of hair loss is increased, the age of onset is lowered, the inconsistency of the skin immune system is caused, and various skin diseases such as atopy and psoriasis are occurring. In addition, despite the young age due to changes in the diet of instant food and meat, the population suffering from obesity is rapidly increasing.
따라서 미적인 차원뿐만 아니라 심각한 사회문제가 되고 있는 여러 가지 병적 현상, 예를 들어, 내인성 노화와 자외선에 의한 주름발생, 기미 또는 주근깨, 비만, 면역불균형 및 탈모 등과 같은 현상을 효과적으로 해결할 수 있는 물질의 개발이 심도 깊게 연구되고 있다.
Therefore, the development of various pathological phenomena that are not only an aesthetic dimension but also a serious social problem, for example, substances capable of effectively solving such phenomena as endogenous aging and wrinkles caused by ultraviolet rays, spots or freckles, obesity, immune imbalance and hair loss This is being studied in depth.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.
Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 주름개선 효과, 탈모 방지 또는 발모촉진 효과, 항산화효과, 항염증 효과가 우수하고 안전성 및 안정성이 높아 피부 부작용이 없는 신규의 물질을 천연유래 화합물을 대상으로 개발하고자 노력하였다. 그 결과, 좀깨잎나무 추출물이 콜라겐 합성을 증가시키고 세포노화를 억제하며, 이를 유효성분으로 포함하는 조성물을 제조하면 그 효능과 안전성이 우수한 피부상태 개선, 항염증, 항산화, 탈모 방지 및 발모 촉진용 조성물을 제공할 수 있음을 확인함으로써, 본 발명을 완성하게 되었다.The present inventors have sought to develop a novel substance which has no wrinkle-reducing effect, hair loss prevention or hair growth promoting effect, antioxidative effect, anti-inflammatory effect, safety and stability, As a result, a composition for improving skin condition, anti-inflammation, antioxidation, hair loss prevention and hair growth promoting excellent efficacy and safety can be obtained by preparing a composition containing an extract of Aspergillus oryzae as an active ingredient by increasing collagen synthesis and inhibiting cell senescence The present invention has been completed.
따라서, 본 발명의 목적은 좀깨잎나무 추출물(Boehmeria spicata (Thunb.) Thunb)를 유효성분으로 포함하는 피부 상태(skin conditions) 개선용 조성물을 제공하는데 있다. Accordingly, an object of the present invention is to provide a composition for improving skin conditions comprising Boehmeria spicata (Thunb.) Thunb as an active ingredient.
본 발명의 다른 목적은 발모 촉진 또는 탈모 방지용 조성물을 제공하는데 있다. Another object of the present invention is to provide a composition for promoting hair growth or preventing hair loss.
본 발명의 또 다른 목적은 항염증용 조성물을 제공하는데 있다.It is still another object of the present invention to provide a composition for anti-inflammation.
본 발명의 또 다른 목적은 항산화용 조성물을 제공하는데 있다.
It is still another object of the present invention to provide a composition for antioxidation.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 분명하게 설명된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명에 있어서, 좀깨잎나무(Spicata ramie)는 쌍떡잎식물 쐐기풀목 쐐기풀과의 반관목이다. 학명은 Boehmeria spicata로 한반도의 함경북도, 평안북도를 제외한 전국 산골짜기 바위틈에 나는 낙엽 반관목으로 높이는 50100cm이다. 긴 잎자루는 붉은빛이 돌며, 잎의 끝은 뾰족하고, 가장자리에는 56개의 큰 톱니가 있으며, 표면에 누운 털이 있다. 꽃은 암수한그루로 이삭꽃차례이고, 잎겨드랑이에 달리며, 담황록색이다. 수꽃이삭은 줄기 밑부분에, 암꽃이삭은 줄기 윗부분에 달린다. 수꽃은 꽃덮이 4장, 수술 4개, 암꽃은 여러 송이가 모여 한 군데에 달리고, 통 모양의 꽃덮이 안에 씨방이 1개, 암술대 1개, 열매는 수과, 긴 도란형, 여러 개가 모여 둥글게 덩어리를 이룬다. 껍질은 섬유가 발달되어 섬유자원으로 이용하고, 어린순은 나물로 먹는다. 한국, 중국, 일본 등지에 분포한다.In the present invention, the Spicata ramie is a semi-shrub with the tree nettle of the dicotyledonous plant. Its scientific name is Boehmeria spicata , which is a deciduous semi-shrub in the rocky crevices of the national valley except North Hamgyong province and Pyongan province in the peninsula. The long petiole is reddish, the tip of the leaf is pointed, there are 56 large sawtooths on the edge, and there is hairs on the surface. The flower is a single male and an inflorescence of Isaac, running on the axil of the leaf, and yellow green. The male flower is on the bottom of the stem, and the female flower is on the top of the stem. The male flower has 4 perianths, 4 stamens, and the female flower is gathered in one place. In the tubular perihelion, one ovary and one style, the fruit is aquatic, long obovate, and several rounds. The skin is developed by fibers and used as a fiber resource, and the young seeds are eaten as herbs. It is distributed in Korea, China and Japan.
본 발명에 있어서, 좀깨잎나무 추출물 추출물은 좀깨잎나무 추출물의 전초, 잎, 뿌리, 줄기, 꽃 등을 통상의 방법에 의하여 추출하거나 이로부터 분리된 주름개선의 예방 또는 치료 활성을 가지는 물질을 말한다. 또한, 상기 추출물은 통상의 방법에 의하여 좀깨잎나무 추출물로부터 추출한 추출액뿐만 아니라 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 말한다.In the present invention, the extract of Z. ricotta extract refers to a substance having the activity of preventing or treating wrinkles, which is extracted from the extract, leaves, roots, stems, flowers, In addition, the above-mentioned extract refers not only to the extracts extracted from Aspergillus odorata extract by conventional methods, but also to the dried powder thereof or all the forms formulated using the same.
본 발명에서 좀깨잎나무 추출물 추출물은 물 또는 유기 용매를 사용하여 추출할 수 있는데, 추출한 액은 액체 형태로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 상기 유기용매는 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매이며, 추출물의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. 추출하는 유기용매에 따라 추출물의 유효성분의 추출정도와 손실정도가 차이가 날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출 방법은 특별히 제한되지 않고, 예를 들어 냉침 추출, 초음파 추출, 환류 냉각 추출 등이 있다.In the present invention, the Aspenstock extract can be extracted with water or an organic solvent, and the extracted solution can be used in a liquid form or can be used by concentration and / or drying. The organic solvent may be selected from the group consisting of methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethylsulfoxide , 3-butylene glycol, propylene glycol, or a mixed solvent thereof. The extract can be extracted at room temperature or with heating under the condition that the active ingredient of the extract is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the extract may differ. Therefore, an appropriate organic solvent should be selected and used. The extraction method is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction.
여과는 추출액으로부터 부유하는 고체 입자를 제거하는 과정으로, 면, 나일론 등을 이용하여 입자를 걸러 내거나 한외여과, 냉동여과법, 원심분리법 등을 사용할 수 있으나, 이에 제한되지 않는다. 또한, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 크로마토그래피)에 의한 분리 과정을 추가로 포함할 수 있다. 여액을 건조하는 단계는 동결건조, 진공건조, 열풍건조, 분무건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다. 경우에 따라, 최종 건조된 추출물을 분쇄하는 공정을 추가할 수 있다.
Filtration is a process of removing suspended solid particles from an extract, and may be performed by filtering particles using a cotton, nylon, or the like, or by ultrafiltration, freezing filtration, centrifugation, etc., but is not limited thereto. In addition, it may further comprise a separation process by various chromatographies (size, charge, hydrophobicity or affinity chromatographic). The step of drying the filtrate includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like. In some cases, a step of pulverizing the final dried extract may be added.
본 발명의 일 양태에 따르면, 본 발명은 좀깨잎나무 추출물(Boehmeria spicata (Thunb.) Thunb)를 유효성분으로 포함하는 피부 상태(skin conditions) 개선용 조성물로서, 상기 피부 상태는 피부 노화 방지 또는 피부 주름 개선인 것을 특징으로 하는 피부 상태 개선용 조성물을 제공한다.
According to one aspect of the present invention, there is provided a composition for improving skin conditions comprising, as an active ingredient, Boehmeria spicata (Thunb.) Thunb extract, wherein the skin condition is skin aging- Wherein the composition for skin condition improvement is characterized by being improved.
본 발명에서 사용되는 용어 피부상태 개선은 피부상태의 모든 형태의 호전 및 양호화를 의미하며, 바람직하게는 피부 노화 방지 및 피부 주름 개선을 의미한다.The term skin condition improvement as used in the present invention means improvement and improvement in all forms of skin condition, and preferably means prevention of skin aging and improvement of skin wrinkles.
본 발명의 피부상태 개선용 조성물은 피부 노화 방지 또는 피부 주름 개선의 용도를 갖는다. 본 발명의 조성물은 세포독성도 낮으면서도, 섬유아세포 보호 작용 및 콜라겐 합성의 촉진 등의 분자적 기전을 통하여 우수한 주름 개선 효능을 발휘하며, 이는 하기의 실시예에 의해 명확하게 확인된다. 본 발명의 조성물의 용도인 피부 노화 방지 및 피부 주름 개선은 통상적인 피부 보호용도(주름의 예방, 주름의 제거, 자외선으로 인한 피부 손상의 완화, 개선, 예방 또는 치료 등)를 포함하는 것으로 해석된다.
The skin condition improving composition of the present invention has a use for preventing skin aging or improving skin wrinkles. The composition of the present invention exhibits an excellent wrinkle-reducing effect through a molecular mechanism such as a fibroblast-protecting action and promotion of collagen synthesis while being low in cytotoxicity, which is clearly confirmed by the following examples. The use of the composition of the present invention for preventing skin aging and improving skin wrinkles is interpreted to include conventional skin protection uses (such as prevention of wrinkles, removal of wrinkles, reduction of skin damage due to ultraviolet rays, improvement, prevention or treatment) .
본 발명의 다른 양태에 따르면, 본 발명은 좀깨잎나무 추출물을 유효성분으로 포함하는 발모 촉진 또는 탈모 방지용 조성물을 제공한다. According to another aspect of the present invention, there is provided a composition for promoting hair growth or preventing alopecia, comprising Aspergillus odorosa extract as an active ingredient.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 발모 촉진 또는 탈모 방지에 매우 효과적으로 작용한다. 본 명세서에서 사용되는 용어 탈모 방지 또는 발모 촉진은 동일한 의미로 사용되며, 이는 당업계에서 이용되는 또 다른 용어 양모 또는 육모 촉진과 동일한 의미를 가진다.
According to a preferred embodiment of the present invention, the composition of the present invention is very effective in promoting hair growth or preventing hair loss. As used herein, the term hair loss prevention or hair growth promoting is used interchangeably, which has the same meaning as another term wool or hair growth promotion used in the art.
본 발명의 다른 양태에 따르면, 본 발명은 좀깨잎나무 추출물을 유효성분으로 포함하는 항염증용 조성물을 제공한다. According to another aspect of the present invention, there is provided an antiinflammatory composition comprising Aspergillus oryzae extract as an active ingredient.
본 발명의 조성물은 좀깨잎나무 추출물을 유효성분으로 포함하여 염증과 관련된 면역관련 반응을 억제하는 효과를 가진다. 구체적으로, 유효성분인 좀깨잎나무 추출물은 일반적으로 염증반응에서 통증에 주요한 작용을 하는 COX-2에 작용한다. 프로스타글란딘(PGE2)의 전구체인 아라키돈산은 세포막에 존재하는데, 사이클로옥시게네이즈 경로를 지나면서 프로스타글란딘이 생성된다. 생성된 프로스타글란딘은 알러지와 염증 과정에서 분비되는 화학적 매개체 역할을 하며 통각 신경을 자극하거나 염증반응을 지속시키거나 암 발생에 영향을 준다. 그러므로 COX-2 활성을 억제하는 물질은 염증반응을 억제할 수 있는 물질일 가능성이 매우 높다.The composition of the present invention has an effect of inhibiting the inflammation-related immune-related reaction by containing an extract of Aspergillus species as an active ingredient. Specifically, the extract of Aspergillus species, the active ingredient, acts on COX-2, which is a major factor in pain in inflammatory reactions. Arachidonic acid, a precursor of prostaglandin (PGE2), is present in the cell membrane, and prostaglandins are produced through the cyclooxygenase pathway. The resulting prostaglandins act as chemical mediators secreted during allergic and inflammatory processes, stimulating painful nerves, sustaining an inflammatory response, or affecting cancer development. Therefore, a substance that inhibits COX-2 activity is highly likely to be a substance capable of inhibiting an inflammatory reaction.
한편, COX-2의 억제는 다수의 염증 증상을 감소시키는 것으로 보고되어 있고, 다수의 중요한 소염제(예: 이부프로펜 및 셀레콕시브)는 COX-2 활성을 억제함으로써 작용한다. 본 발명의 조성물은 COX-2 활성을 효율적으로 억제하는 면역조절기능을 가진다. On the other hand, inhibition of COX-2 has been reported to reduce a number of inflammatory symptoms, and many important anti-inflammatory agents such as ibuprofen and celecoxib act by inhibiting COX-2 activity. The composition of the present invention has an immunoregulatory function that effectively inhibits COX-2 activity.
따라서, 본 발명의 항염증용 조성물은 면역반응을 억제하여 예방 또는 치료될 수 있는 다양한 질환, 질병 또는 이상 상태에 적용될 수 있다. 본 발명의 조성물에 의해 예방 또는 치료될 수 있는 염증 관련 질환은, 예를 들어, 수포성 유천포창, 반흔성 유천포창, 원판성 낭창, 홍반성 루프스, 건선, 전신성 홍반성 루프스, 알러지 및 아토피를 포함하나, 이에 한정되는 것은 아니다. 본 발명의 항염증용 조성물은, 바람직하게는 아토피의 예방 또는 치료에 이용된다.
Accordingly, the anti-inflammatory composition of the present invention can be applied to various diseases, diseases or abnormal conditions which can be prevented or treated by inhibiting the immune response. Inflammatory diseases that can be prevented or treated by the composition of the present invention include, for example, pemphigus vulgaris, scarred pemphigus, scarlet lupus, hypersplenic lupus, psoriasis, systemic lupus erythematosus, allergy and atopy But is not limited thereto. The anti-inflammatory composition of the present invention is preferably used for prevention or treatment of atopy.
본 발명의 다른 양태에 따르면, 본 발명은 좀깨잎나무 추출물을 유효성분으로 포함하는 항산화용 조성물을 제공한다. 본 발명 조성물의 유효성분인 좀깨잎나무 추출물은 다양한 자극으로 인해 발생하는 활성산소(ROS)로 인한 산화적 손상으로부터 미토콘드리아를 보호하는 작용을 통해 항산화 효과를 발휘한다.
According to another aspect of the present invention, there is provided an antioxidative composition comprising Aspergillus odorata extract as an active ingredient. The extract of Aspergillus species, which is an active ingredient of the composition of the present invention, exerts antioxidative effect by protecting mitochondria from oxidative damage caused by active oxygen (ROS) generated by various stimuli.
본 발명의 항산화용 조성물은 산화 스트레스를 억제 또는 제거하여 예방 또는 치료할 수 있는 다양한 질환, 질병 또는 이상 상태에 적용될 수 있다. 본 발명의 조성물에 의해 예방 또는 치료될 수 있는 항산화-관련 질환은, 아테롬성 동맥경화증, 관상동맥질환, 심장동맥 재협착, 재관류 손상, 파킨슨병 또는 알츠하이머 질환과 같은 신경변성 질환, 뇌졸중, 암, 노화, 심혈관 질환, 골다공증, 중추신경계 장애, 말초혈관 질환 및 호흡곤란을 포함하나, 이에 한정되는 것은 아니다. 가장 바람직하게는, 본 발명의 항산화용 조성물은 노화의 예방 또는 치료에 이용된다.The antioxidant composition of the present invention can be applied to various diseases, diseases or abnormal conditions which can be prevented or treated by suppressing or eliminating oxidative stress. Antioxidant-related diseases that can be prevented or treated by the composition of the present invention include, but are not limited to, atherosclerosis, coronary artery disease, coronary artery restenosis, reperfusion injury, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, stroke, , Cardiovascular disease, osteoporosis, central nervous system disorders, peripheral vascular disease, and dyspnea. Most preferably, the antioxidant composition of the present invention is used for prevention or treatment of aging.
많은 질환상태와 자유라디칼 손상과의 상관관계는 널리 입증되어 있으며 효소, 이온채널, 구조 단백질 및 막지질을 포함하는 많은 세포 구성성분이 반응성 자유 라디칼 종에 대한 잠재적인 표적물이다(Rice-Evans C, Mol Aspects of Med 13(1):1-111(1992)). 상기 잠재적인 표적물과 자유 라디칼의 반응은 특정범위의 세포기능을 손상시켜 병리학적 변화를 유발하여 궁극적으로 세포를 사멸시킨다. 또한, 생리학적인 산화에 의해 다양한 질병이 야기되는 것은, 미국 특허 제5750351호, 제 5773209호 제5773231호 및 제5846959호에 개시되어 있다.The association of many disease states with free radical damage has been well established and many cellular constituents including enzymes, ion channels, structural proteins and membrane lipids are potential targets for reactive free radical species (Rice-Evans C , Mol Aspects of Med 13 (1): 1-111 (1992)). The reaction of these potential targets with free radicals impairs a certain range of cellular function, causing pathological changes and ultimately killing the cells. It is also disclosed in U.S. Patent Nos. 5750351, 5773209, 5773231 and 5846959 that various diseases are caused by physiological oxidation.
구체적인 실시 양태에서, 본 발명의 항산화용 조성물은 활성산소의 생성을 유도하는 로테논(rotenone)의 자극 및 그에 의해 유도되는 활성산소로 인한 산화적 손상으로부터 세포내 미토콘드리아를 보호하는 효과를 나타낸다.
In a specific embodiment, the antioxidant composition of the present invention has an effect of protecting intracellular mitochondria from stimulation of rotenone inducing the production of active oxygen and oxidative damage caused by active oxygen induced thereby.
본 발명의 바람직한 구현예에서, 상기 좀깨잎나무 추출물의 유효성분은 전체 조성물을 기준으로 하여 0.00001 내지 15.0 중량%, 보다 바람직하게는 0.0001 내지 10 중량%, 가장 바람직하게는 0.0001 내지 5 중량%이다. In a preferred embodiment of the present invention, the active ingredient of the Schizandra chinense extract is 0.00001-15.0 wt%, more preferably 0.0001-10 wt%, and most preferably 0.0001-5 wt%, based on the total composition.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 화장료 조성물로 제조될 수 있다.According to a preferred embodiment of the present invention, the composition of the present invention can be prepared with a cosmetic composition.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서의 좀깨잎나무 추출물 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다. 본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다. 본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. The components contained in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to the extract of Aspergillus species as an active ingredient, and include conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, And a carrier. The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream. When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
본 발명의 조성물은 약제학적 조성물로 제조될 수 있다.The compositions of the present invention may be prepared with pharmaceutical compositions.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구 투여할 수 있으며, 바람직하게는 비경구 투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably topical application by application.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약제학적 조성물의 투여량은 성인 기준으로 0.001-100 /㎏ 범위 내이다. 또한 외용제인 경우에는 성인 기준으로 1.0 내지 3.0 ㎖의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . The dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 / kg on an adult basis. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day and continue for 1 month or longer. However, the dose is not intended to limit the scope of the present invention.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액, 시럽제 또는 유화액 형태이거나 엑스제, 산제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
또한, 본 발명의 조성물은 식품 조성물로 제조될 수 있다.In addition, the composition of the present invention can be manufactured into a food composition.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 좀깨잎나무 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 다이사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)]를 사용할 수 있다.When the composition of the present invention is prepared with a food composition, it contains not only an extract of Aspergillus species as an active ingredient but also a component that is ordinarily added during the manufacture of a food, for example, a protein, a carbohydrate, a fat, a nutrient, . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Daisaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavors (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 좀깨잎나무 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
한편, 본 발명의 구체적 실시예에서 좀깨잎나무 추출물에 대한 피부누적 자극시험 결과 좀깨잎나무 추출물은 천연물질로서 인체에 무해한 물질임을 확인하였다. 따라서, 본 발명의 좀깨잎나무 추출물은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 화장료, 약제학적 및 식품 조성물에 안전하게 적용할 수 있다.Meanwhile, in a specific example of the present invention, the cumulus stimulation test for the extract of Aspergillus species showed that it was a harmless substance as a natural substance. Therefore, the extract of A. schistosus according to the present invention has little toxicity and side effects, so it can be safely used even in long-term use, and can be safely applied to cosmetic, pharmaceutical and food compositions as described above.
본 발명은 또한 상기 조성물을 개체에 투여하여 개체의 피부상태를 개선하거나 염증반응을 억제하거나 개체 내 산화 스트레스를 억제할 수 있다.The present invention also provides a method for improving the skin condition of an individual, inhibiting an inflammatory reaction, or inhibiting oxidative stress in a subject by administering the composition to an individual.
본 발명에 있어서, 개체는 피부의 불량한 상태, 예를 들어 주름, 흑화, 탈모 등을 개선또는 예방하고자 하거나, 염증 또는 이와 관련된 질환의 치료 또는 예방을 하고자 하거나, 또는 산화 스트레스에 의한 질환, 질병 또는 이상 상태를 치료 또는 예방을 하고자 하며, 본 발명의 조성물의 투여에 의하여 이들 목적을 달성할 수 있는 인간과 포유동물, 예를 들어 개, 돼지, 말, 소 등을 의미한다. In the present invention, an individual is to treat or prevent a poor condition of skin such as wrinkles, blackening, hair loss, etc., to treat or prevent inflammation or related diseases, or to treat diseases or diseases caused by oxidative stress Refers to humans and mammals, such as dogs, pigs, horses, cows, etc., which are intended to treat or prevent an abnormal condition and which can achieve these objectives by administration of the composition of the present invention.
본 발명에 있어서, 투여는 어떠한 적절한 방법으로 개체에게 소정의 물질을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 조성물은 활성 물질이 표적 대상, 예를 들어, 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.In the present invention, administration refers to the introduction of a predetermined substance into a subject by any appropriate method, and the administration route of the composition of the present invention may be administered orally or parenterally through any conventional route so long as it can reach the target tissue . The composition of the present invention may also be administered by any device capable of transferring the active substance to a target subject, for example, a cell.
상술한 피부상태, 염증억제, 산화 스트레스, 및 이들로부터 발생하는 질환, 질병 또는 이상은 본 발명의 조성물의 개체 내 투여에 의하여 개선, 호전, 예방 또는 치료 등의 목적을 달성할 수 있음은 상술한 내용 및 하기에 기술된 실시예 등을 통하여 당업계의 통상의 지식을 가진 자에 의하여 이해될 것임은 물론이다.
The above-described skin conditions, inflammation suppression, oxidative stress, and diseases, diseases, or abnormalities resulting therefrom can achieve the object of improving, improving, preventing, or treating by administration of the composition of the present invention in the individual, It will be understood by those skilled in the art that the present invention is not limited to the above-described embodiments.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명의 조성물은 좀깨잎나무 추출물을 유효성분으로 포함한다.(I) The composition of the present invention contains Aspergillus oryzae extract as an active ingredient.
(ⅱ) 본 발명의 조성물에서 유효성분으로 이용되는 좀깨잎나무 추출물은 우수한 피부 주름 개선, 발모 촉진 및 탈모 방지 효과를 나타낸다. 좀깨잎나무 추출물은 콜라겐 합성의 촉진, 섬유아세포 보호 작용 등의 분자적 기전을 통하여 우수한 주름 개선 효능을 발휘하며, 발모 촉진 또는 탈모 방지 효과를 가진다. (Ii) The extract of Aspergillus odorus, used as an active ingredient in the composition of the present invention, exhibits excellent skin wrinkles, promotes hair growth, and prevents hair loss. The extracts of Z. ricotta exhibit excellent wrinkle-reducing effects through promoting the collagen synthesis and protecting the fibroblast from the molecular mechanism, and have the effect of promoting hair growth or preventing hair loss.
(ⅲ) 본 발명의 조성물에서 유효성분으로 이용되는 좀깨잎나무 추출물은 염증과 관련된 면역관련 반응을 억제하는 효과, 미토콘드리아 활성산소 제거하는 항산화 효과를 가진다.(Iii) The extract of Aspergillus odorus, used as an active ingredient in the composition of the present invention, has an antioxidant effect for suppressing immune related reactions and mitochondrial free radicals.
(ⅳ) 또한, 세포독성 및 피부 부작용이 없어 화장료, 약품 및 식품 조성물에 안전하게 적용할 수 있다.
(Iv) In addition, it can be safely applied to cosmetics, medicines and food compositions without cytotoxicity and skin side effects.
도 1은 좀깨잎나무 추출물에 의한 콜라겐(타입 I 콜라겐) 생합성 촉진 효과를 보여주는 그래프이다.
도 2은 좀깨잎나무 추출물에 의한 콜라겐분해효소 억제 효과를 보여주는 그래프이다.
도 3은 좀깨잎나무 추출물의 산화스트레스로 유도된 세포노화억제 효과를 보여주는 그래프이다.
도 4은 좀깨잎나무 추출물의 모낭 진피 유두 세포 증식 효과를 보여주는 그래프이다. FIG. 1 is a graph showing the effect of accelerating the collagen (type I collagen) biosynthesis by Aspergillus species extract.
FIG. 2 is a graph showing collagenase inhibitory effect by Aspergillus oryzae extract.
FIG. 3 is a graph showing the oxidative stress-induced cytostatic effect of Schizandra chinensis extract.
Fig. 4 is a graph showing the effect of daphnia magna extract on follicular dermal papilla cell proliferation.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
좀깨잎나무 추출물 제조Mulberry leaf extract production
본 발명의 좀깨잎나무 추출물은 하기와 같이 제조될 수 있다.The Schizandra chinense extract of the present invention can be prepared as follows.
좀깨잎나무 전초를 음건하여 마쇄한 후, 건조된 시료의 중량의 약 0.5 내지 20배, 바람직하게는 약 1 내지 15배 분량의 물, 에탄올, 메탄올 등과 같은 C1 내지 C4의 저급 알코올 또는 약 1:0.1 내지 1:10, 바람직하게는 1:0.2 내지 1:9의 혼합비(/)를 갖는 물과 메탄올의 혼합용매로, 실온에서 약 0.5 내지 48시간, 바람직하게는 1 내지 30시간 동안 교반추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여, 바람직하게는 초음파 추출한 후 수득한 추출액을 여과, 감압농축 또는 건조하여 본 발명의 추출물을 수득할 수 있다.The shrubs are shredded and shredded and then washed with water to a volume of about 0.5 to 20 times, preferably about 1 to 15 times the weight of the dried sample, C1 to C4 lower alcohols such as ethanol, methanol or the like, or about 1: 0.1 For about 0.5 to 48 hours, preferably 1 to 30 hours, at room temperature with a mixed solvent of water and methanol having a mixing ratio (/) of 1: 1 to 1: 10, preferably 1: 0.2 to 1: The extract of the present invention can be obtained by using an extraction method such as extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, preferably after ultrasonic extraction, by filtration, concentration under reduced pressure or drying.
좀깨잎나무 추출물의 콜라겐 합성 증진 효과 측정Measurement of Collagen Synthesis Enhancement Effect of Leaf Extract
콜라겐 생합성능은 사람유래 섬유아세포에 대한 세포실험으로 합성정도를 측정할 수 있다. 콜라겐 생합성능 실험은 인체유래 정상 섬유아세포(human normal fibroblast, 아주대 피부과)를 DMEM 배지가 들어 있는 24-well plate에 접종시키고(2 × 105 세포/well), 5% 농도의 CO2 배양기에 37℃로 24시간 동안 배양하였다. 24시간 후, 각 well에서 배지를 제거하고 농도별로 시료를 처리한 다음 24시간 동안 다시 배양하였다. 24시간 후, 세포배지를 수집하여 샘플을 제조하였다.Collagen biosynthesis performance can be measured by cell experiments on human fibroblasts. Collagen biosynthesis experiments were performed by inoculating human normal fibroblasts (2 × 10 5 cells / well) into DMEM medium and incubating them in a 5% CO 2 incubator Lt; 0 > C for 24 hours. After 24 hours, the medium was removed from each well, the samples were treated at different concentrations, and then cultured again for 24 hours. After 24 hours, the cell culture medium was collected to prepare a sample.
콜라겐 합성량은 콜라겐 측정 키트(Procollagen Type I C-peptide EIA kit MK101, 다카라, 일본)를 이용하여 프로콜라겐(procollagen) 타입 I C-펩타이드(Type I C-peptide: PICP)의 양을 측정하였다. 자세한 시험방법은 (주)다카라의 키트 설명서에 따라 수행하였다. 콜라겐 생합성 관찰결과를 하기 도 1에 나타내었다. 도 1에 나타낸 바와 같이, 좀깨잎나무 추출물은 인체유래 섬유아세포에서 콜라겐 생성을 농도 의존적으로 증가시켰다.The amount of collagen synthesis was determined by measuring the amount of procollagen type I C-peptide (Type I C-peptide: PICP) using a collagen measurement kit (Procollagen Type I C-peptide EIA kit MK101, Takara, Japan). The detailed test method was performed according to the instructions of the Takara Co., Ltd. kit. The result of observation of collagen biosynthesis is shown in Fig. As shown in Fig. 1, the extract of Asanomycetes japonica increased collagen production in a concentration-dependent manner in human-derived fibroblasts.
좀깨잎나무 추출물의 콜라겐분해효소 억제 효과 측정Measurement of collagenase inhibitory effect of Aspergillus oryzae
콜라겐을 분해하는 효소인 콜라게네이즈의 활성정도를 측정하는 방법으로 콜라게네이즈에 대한 항체를 이용하였다. 콜라게네이즈 활성을 유도하는 물질로 알려진 종양괴사인자 알파(Tumor necrosis factor, TNF-alpha(Sigma))를 처리하였다. 전체적인 시험은 판매회사의 프로토콜에 따라 실시하였다. 타입 I 콜라게네이즈 어세이 키트 (Amersham Biosciences, RPN2629)를 이용하였으며, ELISA 판독기(Bio-Tek ELx808 Series Ultra Microplate Reader, 영국)로 흡광도를 측정하였다. 측정된 표준치는 평균 표준편차의 형태로 표시하였고 SPSS/PC+ 프로그램을 이용하여 t-test로 유의성을 검정하였고 그 결과를 하기 도 2에 나타내었다. 도 2에 나타낸 바와 같이, 좀깨잎나무 추출물은 인체유래 섬유아세포에서 종양괴사인자 알파에 의해서 유도된 콜라겐 분해효소 활성을 농도-의존적으로 억제시켰다.An antibody against collagenase was used as a method for measuring the activity of collagenase, an enzyme that degrades collagen. (Tumor necrosis factor, TNF-alpha (Sigma)), a substance known to induce collagenase activity. The overall test was conducted according to the protocol of the sales company. Absorbance was measured with a Type I collagenase assay kit (Amersham Biosciences, RPN2629) using an ELISA reader (Bio-Tek ELx808 Series Ultra Microplate Reader, UK). The measured standard values were expressed in the form of mean standard deviation, and the significance was tested by t-test using the SPSS / PC + program. The results are shown in FIG. As shown in Fig. 2, A. zeaxus extract inhibited the collagenase activity induced by tumor necrosis factor alpha in human-derived fibroblasts in a concentration-dependent manner.
좀깨잎나무 추출물을 포함하는 화장료의 주름개선 효과 측정Measurement of wrinkle-improving effect of cosmetics containing extract
좀깨잎나무 추출물을 포함하는 화장료의 주름 개선효과를 임상 시험을 통하여 측정하였다. 제조예 1(좀깨잎나무 추출물을 각각 0.01%, 0.05% 및 1% 함유한 영양 크림) 및 비교 제조예(정제수를 함유한 영양 크림)에서 제조한 영양 크림을 사용하였
The wrinkle - improving effect of cosmetics containing zebo leaf extract was evaluated by clinical studies. Preparation Example 1 (Nutritional cream containing 0.01%, 0.05% and 1% of each of the extracts of Aspergillus species) and nutritional cream prepared in Comparative Example (nutritional cream containing purified water) were used
주름개선 효과는 피부탄력 변화의 측정을 통해 평가하였다. 피부탄력의 측정은 온도 24∼26, 습도 38∼40%로 일정하게 유지되는 조건에서 건강한 여성 30명(25∼35세)을 대상으로 제조예 1 크림의 3종류와 비교 제조예의 영양 크림을 각각 피검자의 얼굴에 1일 2회씩 3개월 동안 사용하게 한 후, Cutometer SEM 474(Courage + Khazaka, Cologne, 독일)를 이용하여 피부탄력도를 측정하였으며, 판정기준은 피부탄력이 없는 경우를 0, 많은 경우를 5로 하여 상대적인 값을 비교하였다. 시험결과는 하기 표 1에 나타내었다.The effect of improving wrinkles was evaluated by measuring changes in skin elasticity. Skin elasticity was measured in 30 healthy women (25-35 years old) under the condition that the temperature was maintained at 24 to 26 and the humidity was 38 to 40%. Three kinds of the cream of Preparation Example 1 and the nutritional cream of Comparative Preparation Example were respectively The skin elasticity was measured using a cutometer SEM 474 (Courage + Khazaka, Cologne, Germany) for 3 months, twice a day on the subject's face. The criteria for skin elasticity were 0, And the relative values were compared. The test results are shown in Table 1 below.
상기 표 1의 결과를 통해, 본 발명의 제조예 1이 비교 제조예에 비해 피부탄력도가 월등히 향상됨을 확인하였다. 이를 통해 좀깨잎 추출물의 주름개선 효과를 하였으며, 또한 좀깨잎나무 추출물의 함유 농도가 증가함에 따라 피부탄력도도 농도-의존적으로 향상됨을 확인하였다.
From the results of Table 1, it was confirmed that the skin elasticity of Preparation Example 1 of the present invention was significantly improved as compared with the comparative preparation example. As a result, it was confirmed that the skin elasticity was increased in a concentration - dependent manner as the concentration of the extract was increased.
제조예 1. 좀깨잎나무 추출물 추출물을 함유한 크림의 제조Production Example 1. Preparation of a cream containing an extract of Aspergillus species
좀깨잎나무 추출물을 포함하는 영양 크림의 조성은 하기 표 2와 같다. 수상인 정제수, 트리에탄올 아민 및 프로필렌글리콜을 70℃로 가열하고 용해시키고, 여기에 유상인 지방산, 유성성분, 유화제 및 방부제를 70℃로 가열하여 용해한 액을 첨가하여 유화시켰다. 유화가 완료된 후 상기 용액을 45℃로 냉각시키고 좀깨잎나무 추출물 및 향을 첨가하고 분산시킨 다음 30℃로 냉각하였다.The composition of the nutritional cream containing zebo leaf extract is shown in Table 2 below. The aqueous phase, purified water, triethanolamine and propylene glycol were heated and dissolved at 70 DEG C, and a fatty acid, an oily component, an emulsifier and an antiseptic agent were heated to 70 DEG C to dissolve the emulsified liquid. After the emulsification was completed, the solution was cooled to 45 캜, and the leaves were added and dispersed, and then cooled to 30 캜.
경구투여에 의한 항노화 효과Anti-aging effect by oral administration
노화는 모든 생물체에서 나타나는 현상으로 전체 조직 및 기관에 나타난다. 피부는 동물의 경우 개체의 최외곽을 구성하는 가장 면적이 넓은 기관으로 피부에 나타나는 주름은 노화 정도를 가장 쉽게 판별할 수 있는 지표이다. 특히 자외선을 조사할 경우 인위적으로 노화과정을 촉진할 수 있기 때문에 동물시험에서 자외선을 쬔 후 시험물질을 경구나 경피로 투여하여 그 효과를 측정함으로써 그 물질이 실제 항노화 효과가 있는 지를 확인할 수 있다.Aging is a phenomenon that occurs in all organisms and is present in all tissues and organs. Skin is the largest organ of the body that forms the outermost part of an individual in the case of animals. Wrinkles appearing on the skin are the easiest indicators to determine the degree of aging. In particular, since ultraviolet irradiation can artificially accelerate the aging process, it is possible to confirm whether or not the substance has an actual anti-aging effect by measuring the effect of the test substance administered with a light or transdermal patch after ultraviolet light is irradiated in an animal test .
본 발명의 조성물이 광노화 증상에 미치는 영향을 조사하고자 무모생쥐(hairless mouse)를 동물모델로 선정하여 실험하였다. 67 주령의 암컷 무모생쥐(hairless mouse-Skh: HR-1)를 그룹 당 8 마리씩 정상군, UV 대조군, UV/좀깨잎나무 추출물 투여군으로 나누어 실험기간 동안 사육하였다. 정상군과 UV 대조군은 0.5 의 생리식염수를 경구투여하였고, UV/좀깨잎나무 추출물 투여군은 고형분 기준으로 체중 ㎏당 100 의 좀깨잎나무 추출물을 0.5 식염수에 섞어 액체 투여용 주사기를 이용하여 경구 투여하였다. 투여기간은 총 5주로 주 5일 동일한 시간에 투여하였다. 경구투여 후 2주부터 5주까지 UV 대조군, UV/좀깨잎나무 추출물 투여군에 주 3회 태양광과 유사하게 UV를 조사하였다. 실험기간 중 총 UV 조사량은 600 mJ/㎠이 되도록 하였To investigate the effect of the composition of the present invention on photoaging symptoms, hairless mice were selected as animal models. Eighteen female mice (hairless mouse-Skh: HR-1) at 67 weeks of age were divided into the normal group, the UV control group, and the UV / mulberry leaf extract group. Oral administration of 0.5% normal saline solution and UV control group was performed. Oral administration of 100% water extract per 100 kg of body weight was carried out using a liquid syringe. The administration period was 5 weeks in total and 5 days in the same time. From 2 to 5 weeks after oral administration, the UV control group and the UV / Safflower extract group were irradiated with UV light similar to sunlight three times a week. The total UV irradiation amount during the experiment was 600 mJ / ㎠
다. 항노화 효과의 주요 현상으로 주름개선 효과의 객관적 판정을 위하여 부검 전 무모생쥐(hairless mouse)의 등쪽에서 실리콘 폴리머를 이용하여 피부주형(replica)을 채취하였고 마찬가지로 5주 후에 각 샘플 처리군으로 부터 피부주형을 채취하여 항노화 효과 즉 주름개선 효과를 비교하였다. 하기 표 3에서 보여지는 바와 같이, 주름개선정도를 나타내는 R1, R2, R3, R4, R5 모두, 좀깨잎나무 추출물을 투여한 무모생쥐(hairless mouse)에서 투여하지 않은 UV/대조군에 비해 크게 감소한 것을 관찰하였다. 이 결과를 통해 본 발명의 조성물이 피부주름을 개선하는 효과를 가짐을 알 수 있었다. 즉, 경구투여시, 좀깨잎나무 추출물의 주름개선 효과가 나타나 항노화 효과가 있음을 확인할 수 있었다(표 3).All. As a main phenomenon of anti-aging effect, skin replicas were collected from the dorsal side of a hairless mouse before autopsy to determine the effect of improving wrinkles. Likewise, after 5 weeks, The molds were collected to compare the anti-aging effect, that is, the wrinkle-improving effect. As shown in Table 3 below, it was observed that R1, R2, R3, R4, and R5 showing wrinkle improvement degree were significantly decreased compared to the UV / control group which was not administered in hairless mouse administered with Zygomyksis rhizoma extract Respectively. These results indicate that the composition of the present invention has an effect of improving skin wrinkles. In other words, it was confirmed that the wrinkle-improving effect of Asanovoraceae extract was exhibited when it was orally administered (Table 3).
R1 값: 피부의 주름도(Skin roughness), R2 값: 피부의 깊은 주름도(Maximum roughness), R3 값: 피부의 평균주름도(Average roughness), R4 값: 주름 평균깊이(Smoothness depth), R5 값: 피부의 평균 거칠기(Arithmetic average roughness)(International Journal of Cosmetic Science, 27(3):155-60(2005)).R1 value: Skin roughness, R2 value: Maximum roughness of skin, R3 value: Average roughness of skin, R4 value: Smoothness depth, R5 Value: Arithmetic average roughness (International Journal of Cosmetic Science, 27 (3): 155-60 (2005)).
좀깨잎나무 추출물의 인체 피부에 대한 안전성 확인 실험The safety test for the skin of Aspergillus oryzae
좀깨잎나무 추출물이 인체피부에 안전한지 확인하기 위하여, 피부 안전성 검증 실험을 수행하였다. 이를 위해 피부누적자극시험을 실시하였다. 스쿠알렌을 베이스로 좀깨잎나무 추출물을 각각 0.1%, 0.5% 및 1% 첨가한 제형을 제조하고, 이를 사용하여 건강한 30명의 성인을 대상으로 윗팔뚝 부위에 격일로 총 9회의 24시간 누적 첩포를 시행하여 좀깨잎나무 추출물이 피부에 자극을 주는지의 여부를 측정하였다. 첩포 방법은 핀 챔버(Finn chamber, Epitest Ltd, 핀란드)를 이용하였다. 챔버에 상기 각 피부외용제를 15 씩 적하한 후 첩포를 실시하였다. 매회 피부에 나타난 반응의 정도를 하기 수학식 1을 이용하여 점수화 하였으며, 그 결과를 하기 표 4에 나타내었다.In order to confirm the safety of the extract of Asanovorax japonica on human skin, skin safety verification experiment was performed. For this purpose, cumulative skin irritation test was performed. Squalene was used to make a formulation containing 0.1%, 0.5% and 1% of Aspergillus odoratum extract, respectively. A total of 9 times 24 hour cumulative epidermal patches were administered to 30 healthy adults on the upper forearm every other day Whether or not the extracts of Rhododendron japonica extract stimulates the skin was measured. A pin chamber (Finn chamber, Epitest Ltd, Finland) was used as the deposition method. 15 drops of each of the above-mentioned external preparations for skin were dripped into the chamber, followed by applying a patch. The degree of the skin reaction on each occasion was scored using the following
반응도에서 ±는 1점, +는 2점 및 ++는 4점의 점수를 부여하며, 평균반응도가 3 미만일 때 안전한 조성물로 판정된다.A score of ±, a +, and a ++ is given as 1, 2, and 4, respectively, and a safe composition is determined when the average degree of reaction is less than 3.
시험물질
Test substance
반응도Average
대조군
(스쿠알렌)
Control group
(Squalene)
1
One
-
-
-
-
0
0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.09
0.09
[시험군 1]Leaf Extract (0.1%)
[Test group 1]
0
0
-
-
-
-
0
0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.00
0.00
0
0
-
-
-
-
0
0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.00
0.00
좀깨잎나무 추출물(1%)
[시험군 3]
Safflower extract (1%)
[Test group 3]
0
0
-
-
-
-
0
0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.00
0.00
상기 표 4에서 시험군 1, 2 및 3 모두 ±, + 및 ++에 해당하는 사람의 수가 각각 0명, 0명 및 0명이고, 평균 반응도는 각각 0.00, 0.00, 0.00이었다. 그러므로 평균반응도가 3이하의 반응도를 나타내므로, 좀깨잎나무 추출물은 뚜렷한 누적자극 양상을 나타내지 않는 인체 피부에 안전한 물질로 판정되었다.In Table 4, the numbers of persons corresponding to ±, + and ++ in
항염증 효과가 있는지 살펴보기 위하여 면역대식세포(macrophage)인 RAW264.7 세포에서 통상의 방법에 따라 COX(cyclooxygenase) 활성억제능 실험을 시행하였다. COX 활성 측정은 Wadleigh DJ 가 발표한 J Biol Chem. 3;275(9):6259-66(2000)에 따라 실시하였다. RAW264.7 세포를 24-well plate에 24시간동안 배양 후 COX-2 루시퍼레이즈 리포터 벡터를 Superfect(Qiagen)를 이용하여 형질도입하였다. 농도에 따라 희석된 시험물질을 세포에 전처리후 LPS(lipopolysacchride) 200 ng/㎖을 처리하여 COX-2 프로모터를 활성화시켰다. LPS 처리 후 14시간 동안 동일조건에서 배양한 다음 세포를 수집하여 세포 용해액을 얻었다. 세포 용해액을 원심 분리하여 상층액을 따내서 루시퍼레이즈 기질과 반응시킨 후, 루미노미터를 이용하여 COX-2의 발현정도를 측정하였다. 그 결과는 표 5에 나타내었다.In order to investigate the anti-inflammatory effect, the inhibitory effect of COX (cyclooxygenase) was tested in RAW264.7 cells, a macrophage, according to a conventional method. COX activity was measured by J Biol Chem. 3; 275 (9): 6259-66 (2000). RAW264.7 cells were cultured on a 24-well plate for 24 hours, and the COX-2 luciferase reporter vector was transfected using Superfect (Qiagen). The cells were pretreated with the diluted test substance and the cells were treated with LPS (lipopolysaccharide) (200 ng / ml) to activate the COX-2 promoter. The cells were cultured under the same conditions for 14 hours after the LPS treatment, and the cells were collected to obtain a cell lysate. The cell lysate was centrifuged, and the supernatant was collected and reacted with Luciferase substrate, and the degree of COX-2 expression was measured using a luminometer. The results are shown in Table 5.
상기 표 5에서 확인할 수 있듯이, 좀깨잎나무 추출물은 농도-의존적으로 COX-2의 활성을 효과적으로 억제하는 것을 확인했으며, 이를 통해 좀깨잎나무 추출물이 염증억제 효능을 갖고 있음을 알 수 있다.As shown in the above Table 5, it was confirmed that the mulberry leaf extract effectively inhibited the activity of COX-2 in a concentration-dependent manner, indicating that the mulberry leaf extract has an anti-inflammatory effect.
활성산소로부터 섬유아세포 보호효과 및 항노화 효과Fibroblast protection effect and anti-aging effect from active oxygen
사람의 정상 섬유아세포(Human normal fibroblast, 아주대 피부과)를 DMEM 배지가 들어 있는 24-well plate에 접종시키고(2 × 105 세포/well), 5% 농도의 CO2 배양기에 37로 24시간 동안 배양하였다. 24시간 후, 무혈청 DMEM배지로 교환하고 시료를 농도별 처리한 다음, 미토콘드리아 활성산소를 유도하는 것으로 알려진 로테논을 1 uM 함께 처리하였다. 로테논과 실험물질 3일 처리군은 세포생존력을 측정하였고, 6일 처리군은 세포노화 측정 지표인 SA-beta-Gal염색실험을 실시하였다. 염색사진은 도 3에 나타내었다. 도 3에 나타난 것과 같이 로테논에 의해 증가된 SA-beta-Gal 염색 강도가 좀깨잎 추출물이 처리된군에서 감소되는 결과가 관찰되었다.Human normal fibroblasts were inoculated into a 24-well plate containing DMEM medium (2 × 10 5 cells / well), cultured in a 5% CO 2 incubator for 24 h, Respectively. After 24 hours, the cells were exchanged with serum-free DMEM medium, the samples were treated at different concentrations, and then treated with 1 μM of ruthenone, which is known to induce mitochondrial reactive oxygen species. The cell viability was measured by 3-day treatment with rothenone, and the 6-day treatment group was subjected to the SA-beta-Gal staining test, which is an indicator of cell senescence. The dyeing photograph is shown in Fig. As shown in Fig. 3, the SA-beta-Gal staining intensity increased by rotenone was slightly decreased in the group treated with the bark extract.
실험물질 처리 3일 후 MTT(3-(4,5-디메틸티아졸-2-일)-2,5-디페닐테트라졸리움 브로마이드) 방법을 이용하여 세포생존력을 관찰하였다. MTT는 담황색의 기질로서 생세포의 미토콘드리아 내의 호흡쇄 효소에 의해 개열(開裂)하고 암청색의 포르마잔을 생성하였다. 죽은 세포에서는 반응이 일어나지 않으므로 이러한 포르마잔의 생성량은 생세포수 측정에 이용된다. 측정 결과는 표 6에 나타내었다. 세포재생율을 측정하는 수학식은 다음과 같다.Three days after the treatment of the test material, cell viability was observed using MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) method. MTT was cleaved by respiratory chain enzymes in living mitochondria as a pale yellow substrate and produced dark blue formazan. Since the reaction does not occur in dead cells, the amount of formazan produced is used to measure viable cell count. The measurement results are shown in Table 6. The formula for measuring cell regeneration is as follows.
상기 표 6에서 확인할 수 있듯이, 좀깨잎나무 추출물은 로테논에 의해 유도된 섬유아세포 독성 효과를 완화시켰다. 이는 좀깨잎나무 추출물이 미토콘드리아가 활성산소에 의해 손상되는 것을 방어하는 기전을 통해 섬유아세포를 보호하는 것임을 보여준다.As can be seen in the above Table 6, the Aspinus edulis extract relaxed the fibroblast toxicity effect induced by rotenone. This suggests that Zygomycorrhizae extract protects fibroblasts through a mechanism that prevents mitochondria from being damaged by reactive oxygen species.
모낭 진피 유두 세포(Hair follicle dermal papillar cells) 증식 효과Proliferation effect of hair follicle dermal papillar cells
본 발명에 따른 좀깨잎나무 추출물의 탈모방지와 육모 효과를 생체외(in vitro) 실험조건에서 알아보기 위하여, 하기의 실험을 수행하였다In order to investigate the prevention of hair loss and the hair growing effect of Aspergillus odorata extract according to the present invention under in vitro experimental conditions, the following experiment was conducted
모낭 진피 유두 세포를 좀깨잎나무 추출물이 함유된 무혈청 배지에 배양하여 좀깨잎나무 추출물이 세포생존능에 미치는 효과를 관찰하였다. 모낭 진피 유두 세포는 Cell Application사로부터 구입하였고 Hair Follicle Dermal Papilla Cell Growth Medium(Cell Apllications, Inc. USA) 배지를 이용해 배양하였다.The follicular dermal papilla cells were cultured on a serum - free medium supplemented with. The dermal papillary cells were purchased from Cell Application and cultured using the Hair Follicle Dermal Papilla Cell Growth Medium (Cell Apllications, Inc. USA).
모낭 진피 유두 세포 성장용 배지(Hair Follicle Dermal Papilla Cell Growth Medium)를 이용해 배양한 모낭 진피 유두 세포 3 × 105을 6-well plate에 접종하여, 다음 날 무혈청 배지로 1회 세척 후, 좀깨잎나무 추출물이 함유된 무혈청 배지에 72시간 배양하였다. 배양 후 무혈청 배지로 1회 세척 후, 10% MTT를 처리하여 세포와 3시간동안 반응시킨 뒤 OD 값을 측정하여 값을 백분율로 환산하였다. 도 4에 나타낸 바와 같이, 좀깨잎나무 추출물은 모낭 진피 유두 세포의 세포증식을 농도-의존적으로 증가시켰다.The hair follicle dermal papilla cell growth medium (3 × 10 5) was inoculated on a 6-well plate, washed with serum-free medium for one day, And cultured in serum-free medium containing the extract for 72 hours. After incubation, the cells were washed once with serum-free medium, treated with 10% MTT for 3 hours, and the OD value was measured and converted into a percentage. As shown in Fig. 4, the mulberry leaf extract increased the cell proliferation of follicular dermal papilla cells in a concentration-dependent manner.
탈모방지 및 육모효과Hair loss prevention and hair growth effect
본 발명에 따른 좀깨잎나무 추출물의 탈모방지와 육모 효과에 대하여 알아보기 위하여, 하기와 같은 실험을 수행하였다.The following experiment was conducted to examine the hair loss prevention and hair growth effect of A. myrtillus extract according to the present invention.
발모제 조성물의 제조Preparation of hair growth inhibitor composition
좀깨잎나무 추출물을 함유한 발모제 조성물은 하기 표 7의 성분 함량으로 하여 하이드로겔 베이스를 제조하였다. 시험군 1 및 2는 각각 좀깨잎나무 추출물을 포함하는 발모제 조성물이다.The hydrogel base was prepared by using the ingredient contents of Table 7 below.
ingredient
탈모방지 및 육모 효과 측정Prevention of hair loss and hair growth effect measurement
40대에서 60대 후반의 모낭이 위축되어 두피가 매끈매끈한 민 대머리성 탈모증 환자, 전형적인 남성탈모증 환자 및 급성 원형탈모증 환자 등 40명을 4개 군으로 나누고, 1군당 10명씩 할당하였다. 상기 1에서 제조한 발모제를 탈모증 환자의 탈모부위에 1일 2회 각각 3씩 6개월간 적용하였다. 1개월 단위로 탈모 및 육모 상태를 관찰하였다. 비교군으로는 시판중인 목시딜(한미약품)을 사용하였으며, 대조군으로는 50% 에탄올만을 적용하였다.Forty patients in the late 40s and early 60s were shrunken, 40 patients were divided into four groups, including patients with mild scalp baldness alopecia, typical male alopecia, and acute alopecia areata, and 10 patients were allocated to each group. The hair growth inhibitor prepared in the
판정기준은 다음과 같다:The criteria are as follows:
4: 높은 효과 있음 = 신생모가 보임4: High Effective = Newborn Eye
3: 중간 정도의 효과 있음 = 신생모가 보임(솜털)3: moderate effect = newborn eye (fluffy)
2: 약간 효과 있음 = 탈모의 수가 감소함2: slightly effective = reduced number of hair loss
1: 효과 없음 = 전혀 변화가 보이지 않음1: No effect = No change at all
결과는 표 8에 나타냈다.The results are shown in Table 8.
상기 표 8에 나타난 바와 같이, 본 발명의 좀깨잎나무 추출물을 포함하는 발모제를 사용한 탈모증 환자에게서 처치 1개월 또는 2개월째부터 솜털을 비롯한 강모의 신생모가 나타나기 시작하였고, 처치 6개월째에는 80% 이상의 환자에게서 발모 효과가 나타났다. 또한, 신생모가 지속적으로 자라났으며 탈모 현상이 발견되지 않음을 관찰하였다.As shown in Table 8, new hair follicles such as fluffy hair began to appear in the alopecia treated with the hair follicle containing the alopussa larvae extract of the present invention at 1 month or 2 months after treatment, and at the 6th month of treatment, 80% There was a hair growth effect in the patient. In addition, we observed that newborn babies grew continuously and no hair loss phenomenon was found.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
제제예 1 : 화장료 제제Formulation Example 1: Cosmetic preparation
1-1.유연화장수1-1. Longevity of softening
1-2. 영양화장수1-2. Nutritional lotion
1-3. 영양크림1-3. Nourishing cream
1-4. 마사지 크림1-4. Massage cream
1-5. 팩1-5. pack
제제예 2 : 약학적 제제Formulation Example 2: Preparation of a pharmaceutical preparation
2-1. 산제의 제조2-1. Manufacture of Powder
2-2. 정제의 제조2-2. Manufacture of tablets
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
2-3. 캡슐제의 제조2-3. Preparation of capsules
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (9)
The composition according to any one of claims 1 to 6, wherein the composition is a food composition
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130029414A KR20140114709A (en) | 2013-03-19 | 2013-03-19 | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130029414A KR20140114709A (en) | 2013-03-19 | 2013-03-19 | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140114709A true KR20140114709A (en) | 2014-09-29 |
Family
ID=51758334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130029414A KR20140114709A (en) | 2013-03-19 | 2013-03-19 | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140114709A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210073090A (en) * | 2019-12-10 | 2021-06-18 | 재단법인 경기도경제과학진흥원 | Compositions for Improving Skin Wrinkles Using an Extract of Boehmeria tricuspis |
| KR20230025250A (en) * | 2021-08-13 | 2023-02-21 | 경희대학교 산학협력단 | Composition for improving hair loss and promoting hair growth containing Boehmeria spicata |
-
2013
- 2013-03-19 KR KR1020130029414A patent/KR20140114709A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210073090A (en) * | 2019-12-10 | 2021-06-18 | 재단법인 경기도경제과학진흥원 | Compositions for Improving Skin Wrinkles Using an Extract of Boehmeria tricuspis |
| KR20230025250A (en) * | 2021-08-13 | 2023-02-21 | 경희대학교 산학협력단 | Composition for improving hair loss and promoting hair growth containing Boehmeria spicata |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR101781027B1 (en) | Composition for Improving Skin Conditions Comprising Lycium chinense Mill. callus Extract | |
| KR101989407B1 (en) | A composition for promoting melanin synthesis comprising Cirsium japonicum extract | |
| KR20040068986A (en) | Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell factor | |
| KR101436199B1 (en) | Composition for Improving Skin Conditions Comprising Hordenine | |
| KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
| KR101078888B1 (en) | A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof | |
| CN110072516B (en) | Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients | |
| KR102189330B1 (en) | A cosmetic composition for skin improvement comprising bulb extract | |
| JPH1160496A (en) | Medicine for enhancing hyaluronic acid-producing ability | |
| KR101547758B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| JP2001233727A (en) | Cosmetic | |
| KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract | |
| KR101481208B1 (en) | Composition for skin external application comprising cryptotanshinone as the active ingredient | |
| KR101223684B1 (en) | Compositions for Improving Skin Conditions Comprising Afzelin as an Active Ingredient | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| KR100564107B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
| KR101427027B1 (en) | A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis | |
| KR100946584B1 (en) | Cosmetic Composition Comprising Poncirus trifoliata fruit extract and Nymphaea caerulea extract | |
| KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
| KR20060007083A (en) | Skin-whitening cosmetic composition containing extract of rambutan and method for extracting rambutan | |
| KR101743001B1 (en) | Cosmetic composition containing chitosan and propolis extracts | |
| KR20150052907A (en) | Cosmetic composition for Improving Skin Moisturization Comprising the mixed extract of Peach blossom, Sophora japonica flower, Rhubarb and Clove buds as active ingredient | |
| KR20200053082A (en) | A composition for antioxidation, anti-inflammation, antiaging or skin soothing comprising herb complex extracts | |
| KR101244653B1 (en) | Compositions for Improving Skin Conditions Comprising Ginsenoside Rb3 as an Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |